Home
Journals
A-Z Journals
Browse By Subject
Guidelines & Policies
Editorial Policies
Online Submission
Instructions to Authors
Policies
Publication ethics & malpractice statement
Reviewers
Terms and Conditions
Advertising
Conferences
Contact us
Immunotherapy: Open Access
Open Access
ISSN: 2471-9552
Journal Home
Editorial Panel
Editor-in-Chief
Editorial Board
Instructions for Authors
Instructions for Authors
Publication ethics & malpractice statement
Submit Manuscript
Aims and Scope
Articles in process
Special Issue
Archive
Contact
Research Article - (2017) Volume 3, Issue 1
View PDF
Download PDF
Aviscumine (ME-503)-Skin Reaction as significant Factor for its Efficacy Expanded Evaluation of the Results from the Phase II Trial NCT00658437 in Patients with Unresectable stage IV Metastatic Melanoma
Uwe Trefzer
1
,
Ralf Gutzmer
2
,
Tabea Wilhelm
3
,
Florian Schenck
4
,
Katharina C. Kähler
5
,
Volkmar Jacobi
6
,
Klaus Witthohn
7
,
Hans Lentzen
7
*
and
Peter Mohr
8
1
Dermatologikum Berlin, Germany
2
Klinik für Dermatologie, Allergologie und Venerologie. Hauttumorzentrum Hannover (HTZH), Hannover, Germany
3
Charité-Universitätsmedizin Berlin, Hauttumorzentrum Charité (HTCC), Klinik für Dermatologie, Venerologie und Allergologie, Berlin, Germany
4
Hautärzte Zentrum Hannover, Germany
5
Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein-Campus Kiel, Germany
6
Institut für Diagnostische Radiologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Frankfurt/Main, Germany
7
MELEMA Pharma GmbH, Hamburg, Germany
8
Elbe-Klinikum Buxtehude, Dermatologisches Zentrum Buxtehude, Germany
*
Corresponding Author:
Hans Lentzen, MELEMA Pharma GmbH, Hamburg, Germany
Email:
Abstract